OC-01 (varenicline) nasal spray

DRUG3 trials

Sponsors

Oyster Point Pharma, Inc.

Conditions

Dry Eye DiseaseDry Eye Disease (DED)

Phase 2

Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

CompletedNCT03636061

Oyster Point Pharma, Inc.Dry Eye Disease

Start: 2018-08-15End: 2018-09-26Updated: 2021-10-25

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

CompletedNCT03688802

Oyster Point Pharma, Inc.Dry Eye Disease

Start: 2018-09-25End: 2019-09-30Updated: 2021-12-29

Phase 3

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

CompletedNCT04036292

Oyster Point Pharma, Inc.Dry Eye Disease (DED)

Start: 2019-07-23End: 2021-02-05Updated: 2021-11-22

Related Papers

Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?

Optometry and Vision Science2022-12-319 citations

Does Menopausal Status Affect Dry Eye Disease Treatment Outcomes with OC-01 (Varenicline Solution) Nasal Spray? A Post Hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials

Ophthalmology and Therapy2022-11-187 citations

A Single Administration of OC-01 (Varenicline Solution) Nasal Spray Induces Short-Term Alterations in Conjunctival Goblet Cells in Patients with Dry Eye Disease.

2022-06-0210 citations

ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease

Cornea2021-12-2149 citations

Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial.

2021-11-1070 citations